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ABSTRACT
Background As antithrombin III (AT-III) is produced 
in the hepatocytes, its serum activity decreases at the 
time of liver failure, in addition to ischemia reperfu-
sion injury, vascular endothelial dysfunction, and 
disseminated intravascular coagulation (DIC). Here, we 
examined whether the serum AT-III value after hepa-
tectomy could be a prognostic factor for hepatocellular 
carcinoma (HCC).
Methods Of 141 patients who underwent hepatectomy 
for HCC, data for 101 patients in whom serum AT-III 
activity was measured on the first postoperative day 
were extracted. Patients with serum AT-III activity > 
50% and ≤ 50% were assigned to high value (72 cases) 
and low value (29 cases) groups, respectively. We ex-
amined the clinical and prognostic differences between 
these two groups.
Results The average age of enrolled patients (83 men 
and 18 women) was 68.0 years. The 5-year overall sur-
vival rate was 88% and 60% in the high and low value 
groups, respectively (P < 0.01). Furthermore, the 2-year 
relapse-free survival rate was 71% and 54% in the high 
and low value groups, respectively (P = 0.03).
Conclusion This is the first study to demonstrate that 
serum AT-III levels on the first postoperative day may 
serve as a prognostic factor in HCC patients.
Key words Antithrombin III; Hepatectomy; Hepato-
cellular carcinoma; Prognostic factor
Hepatic resection is considered a curative treatment for 
early stage hepatocellular carcinoma (HCC).1 Advances 
in surgical modalities have improved the prognosis of 
HCC patients, but many patients show cancer recurrence 
after surgery. It is imperative to identify patients with 
high risk of recurrence and poor prognosis, as careful 
surveillance of the poor prognosis group may allow early 
detection of recurrent disease and immediate administra-
tion of treatment. Furthermore, some positive interven-
tions such as adjuvant chemotherapy may be possible for 
the high-risk group for cancer recurrence in the future.
The prognostic factors after surgery for HCC are 
extensively studied. As indicated in the Japan Society of 
Hepatology–HCC Guidelines 2017, the major prognostic 
factors are tumor size, tumor number, vascular invasion, 
and liver function. Furthermore, the guidelines state 
that the Glasgow Prognostic Score (GPS), neutrophil-
to-lymphocyte ratio (NLR), and sarcopenia are also 
prognostic factors after hepatectomy.2 Taken together, 
various factors such as tumor stage, liver function, 
inflammation, immunity, and nutrition are involved as 
prognostic factors.
Further, cancer and coagulation are known to be 
closely related. For example, the presence of malignant 
tumors is a possible cause of thrombotic tendency.3 
The hemostatic mechanism of blood is maintained by 
balance between coagulation and activities of fibrino-
lysis factors in the blood. Among them, antithrombin 
III (AT-III) accounts for about 80% of the thrombin 
inactivation in the blood, and is also known to inacti-
vate other coagulation factors (FX IIa, FX Ia, FIXa, 
FXa), plasmin, and kallikrein.4 AT-III is synthesized 
in the liver, and its levels are reduced in disseminated 
intravascular coagulation (DIC).5–9 Moreover, end-stage 
malignancies, severe infection, liver failure, ischemia 
reperfusion injury,10, 11 and vascular endothelial dys-
function decrease the activity of AT-III.
However, whether levels of AT-III post-surgery 
correlate with prognosis remained to be studied. This 
study aimed to determine the clinical and prognostic 
significance of serum AT-III values in patients who 
underwent hepatectomy for hepatocellular carcinoma.
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MATERIALS AND METHODS
Patients
We examined the medical records of consecutive pa-
tients who underwent hepatic resection for HCC at the 
Tottori University Hospital between 2004 and 2013. A 
total of 211 patients with histologically diagnosed HCC 
underwent hepatectomy, and 141 patients underwent 
initial and curative hepatectomy. All patients were 
diagnosed based on contrast-enhanced computed 
tomography (CT) or Gd ethoxybenzyl diethylenetri-
amine pentaacetic acid-enhanced magnetic resonance 
imaging (MRI). We excluded patients diagnosed with: 
1) intrahepatic cholangiocarcinoma tumors based on the 
histological findings of the resected specimens; 2) extra-
hepatic lesions, preoperative vascular invasion, positive 
surgical margins, or macroscopic residual tumor; and 
3) underwent liver transplantation or surgical resection 
combined with ablation therapy. Operative indications 
included following factors: performance status < 3, 
preserved liver function estimated by both indocyanine 
green test and volumetric CT, and good general condi-
tion without serious organ failure. Non-anatomical 
hepatectomy was performed in patients with insufficient 
volume of remnant liver or those with tumors located 
peripherally. Intraoperative temporary inflow clump 
and transfusion were performed on demand from the 
operator and anesthesiologists in charge, respectively. 
Finally, a total of 101 patients were enrolled in the study. 
Patients were divided into two groups based on their 
postoperative (day 1) AT-III activity as: High AT-III 
(> 50%, n = 72) and Low AT-III (≤ 50%, n = 29) group 
(Fig. 1). A cutoff value of 50% was obtained based on 
the receiver operating characteristic (ROC) curve for 
overall mortality.
Written informed consent was obtained from all 
patients prior to surgery. Medical records were reviewed 
retrospectively after approval by the Institutional 
Review Board of the Tottori University Faculty of 
Medicine in accordance with the ethical standards laid 
down in the 1964 Declaration of Helsinki and its later 
amendments (1606A029).
Variables
The data included patient characteristics [age, sex, body 
mass index (BMI), cause of hepatitis, Child-Pugh score, 
and Model for End-Stage Liver Disease (MELD) score], 
tumor characteristics [number of tumors, maximum 
tumor diameter, and alpha-fetoprotein (AFP) level], in-
traoperative data (extent of resection, usage of intermit-
tent total hepatic inflow occlusion, duration of surgery, 
intraoperative hemorrhage volume, and amount of 
intraoperative blood transfusion), and tumor pathologi-
cal findings [capsule formation, microscopic vascular 
invasion, tumor differentiation, and stage of fibrosis of 
non-tumor-bearing liver according to the hepatitis activ-
ity index (HAI)].12 Patients were followed up every 3–6 
months with liver function tests, tumor marker mea-
surements, and imaging examination with CT and/or 
MRI. Data for disease recurrence and survival duration 
were collected from our patients’ database. Major resec-
tion was defined as surgery that included more than two 
Couinaud segments. Tumor recurrence was diagnosed 
Fig. 1. Patient inclusion, flow chart demonstrating patient inclusion.
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based on the findings of either CT or MRI that was 
routinely performed every 6 months. Extrahepatic 
recurrence was defined as recurrence that included only 
extrahepatic metastasis without intrahepatic recurrence. 
Early phase recurrence was defined as recurrence 
diagnosed within two years after the operation, and late 
phase recurrence was defined as recurrence diagnosed 
more than two years after the operation.
Statistical analysis
The primary endpoint of this study was overall survival 
rate, and the secondary endpoints were disease-free 
survival rate and early phase recurrence rate in the high 
AT-III and low AT-III groups. Overall survival (OS) 
and recurrence-free survival (RFS) were determined 
by Kaplan-Meier analysis. Predictive factors of overall 
survival and early recurrence were investigated using 
multivariate analysis based on the variables selected 
by each univariate analysis using a logistic regression 
model and Cox proportional hazards regression model, 
respectively. All continuous values are presented as 
mean ± standard deviation (SD). Statistical analysis was 
performed using the Chi-square test and Fisher’s exact 
test (when less than five variables) for categorical vari-
ables. Welch’s two-sample t-test was used for continu-
ous variables. A P < 0.05 was considered statistically 
significant. R software version 3.1.3. (www.r-project.
org/) was used for comparative statistical analysis. The 
optimal cutoff values of AT-III for survival and recur-
rence were determined by ROC curve analysis. A cutoff 
value for overall mortality was 50% of AT-III with a 
sensitivity and specificity of 42% and 77%, respectively. 
An AT-III activity of 50% was considered as the cutoff 
level in this study.
RESULTS
Postoperative AT-III and patient characteristics
The mean follow-up period of the 101 HCC patients 
enrolled in this study was 65.1 months. Table 1 sum-
marizes patients’ clinicopathological characteristics, 
Table 1. Comparison of clinicopathological features between the low AT-III and high AT-III groups
Low AT-III (n = 29) High AT-III (n = 72) P
Demographic data
 Age (yr) ≥ 75 / < 75 9/20 26/46 0.80
 Gender Male / Female 21/8 63/9 0.12
 BMI (kg/m2) ≥ 25 / < 25 6/23 20/52 0.63
 Cause of hepatitis HBV / HCV 9/11 18/30 0.84
 Child-Pugh grade A/ ≥ B 3/26 1/71 0.07
 MELD score ≥ 10/ < 10 6/23 4/68 0.03*
 AFP value (IU/L) ≥ 20/ < 20 12/17 24/48 0.59
Operative data
 Extent of hepatic resection
Non-anatomical 15/14 27/45 0.28
Major resection 8/21 21/51 1.00
 Blood loss (mL) ≥ 500/ < 500 13/14 29/34 0.25
 Blood transfusion Yes 9 17 0.63
 Pringle maneuver Yes 18 44 1.00
Pathological data
 Tumor number Mt/St 12/17 10/62 < 0.01**
 Tumor size (cm) ≥ 5 / < 5 9/20 16/56 0.50
 Vascular invasion Yes 12/17 21/51 0.34
 TNM stage ≥ II / IA, IB 19/10 30/42 0.05
 Liver cirrhosis (HAI = IV) Yes 11/18 22/50 0.63
*P < 0.05, **P < 0.01. AFP, alpha-fetoprotein; BMI, body mass index; HAI, hepatitis activity index; HBV, hepatitis B virus; HCV, hepa-
titis C virus; MELD score, Model for End-Stage Liver Disease score; Mt, multiple tumor; St, solitary tumor; TNM, tumor (T) nodes (N) 
and metastases (M); yr, year(s).
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and operative and postoperative data in the low AT-III 
and high AT-III groups. AT-III activity significantly 
correlated with Child-Pugh score, MELD score, tumor 
number, and TNM stage. However, AT-III activity 
showed no correlation with operative factors, such as 
hepatic resection type, blood loss, operating time, prin-
gle maneuver, and blood transfusion.
Overall survival and relapse-free survival analysis
Figure 2 shows the prognosis of patients with HCC 
after surgery. Patients in the low AT-III group showed 
significantly poor overall survival than those in high 
AT-III group. Moreover, multivariate analysis identified 
AT-III activity as an independent prognostic factor for 
overall survival in addition to AFP, tumor number, and 
vascular invasion (Table 2). The overall relapse-free 
survival between the low AT-III and high AT-III groups 
tended to be different, although they were not significant 
(Fig. 3). Among the fatal cases, HCC-related deaths 
were 50.0% in the high AT-III group and 61.5% in the 
low AT-III group. On the other hand, death from hepatic 
failure was 18.1% in the high AT-III group and not in 
the low AT-III group.
Risk factors contributing to early phase recurrence
Of 59 patients (58%) who developed HCC recurrence 
after curative resection, early phase recurrence (within 
two years after surgery) was observed in 35 patients 
(59%). Cox regression analysis identified four variables 
as risk factors contributing to early phase recurrence: 
serum AFP level, multiple tumors, and histological 
type. The low AT-III group showed a significantly 
Fig. 2. Overall survival curves of the low AT-III and high AT-III groups. Patients in the low AT-III group showed significantly poor 
overall survival than those in high AT-III group (P < 0.01).
Table 2. Univariate and multivariate analysis for overall survival
Univariate Multivariate
P HR 95% CI P
Child-Pugh ≥ B < 0.01 2.2 0.6–7.9 0.24
AFP ≥ 20 IU/L < 0.01 2.7 1.3–5.8 < 0.01**
Blood transfusion Yes < 0.01 1.4 0.6–3.3 0.42
Tumor number Multiple 0.07 3.9 1.3–12.0 0.02*
Vascular invasion Yes < 0.01 4.1 1.1–14.8 0.03*
TNM stage ≥ II 0.04 0.3 0.1–1.5 0.14
AT-III Low < 0.01 2.6 1.1–6.0 0.03*
*P < 0.05, **P < 0.01. AFP, alpha-fetoprotein; AT-III, antithrombin III; CI, cumulative index; HR, hazards ratio; TNM, tumor (T) nodes 
(N) and metastases (M).
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higher recurrence rate than that in high AT-III group (Fig. 
4). Furthermore, multivariate analysis showed that low 
AT-III level is an independent risk factor for early phase 
recurrence (Table 3).
DISCUSSION
This study investigated the prognostic significance of 
the serum AT-III levels on the first day after hepatec-
tomy for primary liver cancer. The results suggested 
that low AT-III activity on day 1 was a useful predictive 
factor for poor prognosis and early recurrence.
Low AT-III activity is reported to promote progres-
sion in several cancers, including those originating in 
the colon, lung, prostate, and ovary.13, 14 Additionally, a 
previous association study, based on propensity scores 
and multivariate analysis, showed that preoperative 
low AT-III levels may be a risk factor for tumor recur-
rence and prognosis in patients with HCC.15 It has been 
reported that the β-phase half-life of AT-III is reduced 
to 52.7 hours for cirrhosis and dramatically reduced to 
23.9 hours for liver cancer compared to the normal 58.6 
hours.16 Therefore, AT-III is prone to change, especially 
Fig. 3. Recurrence-free survival curves of the low AT-III and high AT-III groups. Between the low AT-III and high AT-III groups 
tended to be different, although they were not significant (P = 0.36).
Fig. 4. Recurrence-free survival curves of the low AT-III and high AT-III groups within 2 years after surgery. The low AT-III group 
showed a significantly higher recurrence rate than that in high AT-III group (P = 0.03).
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after liver cancer treatment.
In this study, we focused on postoperative, but 
not preoperative, AT-III activity. AT-III is a marker 
reflecting liver function, ischemia reperfusion, vascular 
endothelial dysfunction, DIC, sepsis, and so on.6, 17 
As postoperative AT-III activity is associated with 
multiple factors, including preoperative, operative and 
postoperative indicators, we hypothesized that AT-III 
activity might associate with prognosis of HCC patients. 
We focused on AT-III levels on postoperative day-1, as 
AT-III activity on the first day was affected by surgical 
and infectious invasion, which might indicate cancer 
prognosis.18–20 Pereyra D et al. shows that AT-III activ-
ity on POD1 significantly predicted postoperative liver 
dysfunction in patients undergoing liver resection for 
colorectal cancer patients with liver metastasis.21
Postoperative complications are known to adversely 
affect oncological outcomes in various cancers.22, 23 In 
case of HCC, postoperative complications were an inde-
pendent prognostic factor for early phase recurrence.24 
In other words early phase postoperative status may af-
fect cancer prognosis. The duration from surgery to the 
appearance of secondary tumors has been recognized 
as an indicator to distinguish intrahepatic metastasis 
from de novo tumors. Liver tumors developing within 
two years after surgery are believed to be intrahepatic 
metastases.25 This study also examined the impact of 
postoperative status, including AT-III, on intrahepatic 
metastases for HCC.
AT exerts anticoagulant action by binding to 
thrombin and other coagulation factors. Additionally, 
AT exerts direct anti-inflammatory and glycocalyx pro-
tecting actions of the vascular endothelium that controls 
vascular permeability.26 Iwako et al. reported that inad-
equate levels of AT-III increase the susceptibility of AT-
insufficient mice to liver tumorigenesis via increased 
inflammation.27 Recent studies have shown that AT-III 
can suppress the proliferation and migration of HCC 
cells by inhibiting thrombin-induced tumor growth and 
angiogenesis.28–32 However, further basic and clinical 
studies are required to determine the antitumor mecha-
nisms of AT-III.
This study has some limitations. First, the study 
was retrospective in design, meaning that there were 
missing values for several variables. Second, the sample 
size may have affected the statistical robustness of the 
results to certain extent. Third, as preoperative AT-III 
levels were not measured, we could not determine 
which was a more significant prognostic factor, pre- or 
post AT-III. Fourth, we did not assess the administra-
tion of antiviral drugs or interferon. In patients with 
hepatitis B-related HCC, adefovir antiviral therapy re-
duced late HCC recurrence and significantly improved 
overall survival after R0 hepatic resection.33 Finally, 
this was a single-institution cohort study. Therefore, 
further studies would be required to validate our results. 
Furthermore, the study on the clinical significance of 
AT administration for HCC surgery is another topic for 
future research.
In conclusion, this is the first study to demonstrate 
that serum AT-III levels on the first postoperative day 
may serve as a prognostic factor in HCC patients. 
Additionally, low AT-III activity can also serve as a 
predictive marker for early recurrence after HCC sur-
gery. These results demonstrate that close observation 
and intense treatment may be required for HCC patients 
with low AT-III levels after hepatectomy.
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Table 3. Univariate and multivariate analysis for early recurrence
Univariate Multivariate
P HR 95% CI P
AFP ≥ 20 IU/L < 0.01 3.6 1.7–7.6 < 0.01**
Blood transfusion Yes < 0.01 1.7 0.8–3.8 0.2
Tumor number Multiple < 0.01 4.0 1.4–11.4 < 0.01**
Vascular invasion Yes < 0.01 3.0 1.1–8.9 0.04*
TNM stage ≥ II < 0.01 0.6 0.2–2.0 0.38
AT-III Low 0.03 2.2 1.0–4.9 0.04*
*P < 0.05, **P < 0.01. AFP, alpha fetoprotein; AT-III antithrombin III; CI, cumulative index; HR, hazards ratio; TNM, tumor (T) nodes (N) 
and metastases (M).
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